Free Trial
→ Undiscovered Sub-$1 Gold-Silver Royalty Stock Takes Flight (From Digest Publishing) (Ad)tc pixel
NASDAQ:GALT

Galectin Therapeutics Q3 2026 Earnings Date & Estimates

Galectin Therapeutics logo
$3.71 +0.07 (+1.92%)
As of 10/15/2026 04:00 PM Eastern

Galectin Therapeutics is estimated to report Q3 2026 earnings on Friday, November 13, 2026. The conference call is scheduled for 9:30 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Conference Call
9:30 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Galectin Therapeutics in Q3 2026

Galectin Therapeutics is expected to post earnings of -$0.05 per share. In the same quarter a year earlier Galectin Therapeutics reported -$0.13 per share. Galectin Therapeutics last reported on August 14, 2026, posting -$0.14 per share and missing the -$0.09 consensus estimate. Galectin Therapeutics has beaten the consensus EPS estimate in 3 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.05
Prior-Year EPS
-$0.13

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.14 (Missed by -$0.05)
EPS Beat Rate
3 of last 8 quarters

Prepare for the Q3 2026 Call

Galectin Therapeutics Q3 2026 Earnings FAQ

Galectin Therapeutics (NASDAQ:GALT) is estimated to report Q3 2026 earnings on Friday, November 13, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Galectin Therapeutics' Q3 2026 earnings conference call is scheduled for Friday, November 13, 2026 at 9:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Galectin Therapeutics to post earnings of -$0.05 per share for Q3 2026.

Galectin Therapeutics Earnings Headlines

Galectin Therapeutics (NASDAQ:GALT) Stock Crosses Above 200-Day Moving Average - Here's What Happened
October 8, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31098148
Galectin: $105M Debt Conversion Clears The Balance Sheet, But Phase 3 Partnership Is Critical
October 6, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4952168-galectin-105m-debt-conversion-clears-the-balance-sheet-but-phase-3-partnership-is-critical
Bezos… DOOMED
A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X combined - aimed at the $25 trillion AI industry. James Altucher says the plan could cut Amazon out of the AI race and disrupt Blue Origin, with a key deadline landing December 8th.tc pixel
 |  Paradigm Press (Ad)
Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026
October 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/06/3375397/27423/en/galectin-therapeutics-to-present-at-the-american-association-for-the-study-of-liver-diseases-aasld-liver-meeting-2026.html
Galectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 10, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/10/3359434/27423/en/galectin-therapeutics-to-present-at-the-h-c-wainwright-28th-annual-global-investment-conference.html
Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update
August 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/14/3345273/27423/en/galectin-therapeutics-reports-june-30-2026-financial-results-and-provides-business-update.html
See More Galectin Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Galectin Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Galectin Therapeutics and other key companies, straight to your email.

About Galectin Therapeutics

Galectin Therapeutics (NASDAQ:GALT) (NASDAQ:GALT) is a biotechnology company focused on developing therapies that target galectin-3, a protein believed to play a role in fibrosis, inflammation and cancer biology. The company’s research is aimed at addressing serious chronic diseases for which treatment options remain limited.

Galectin Therapeutics’ lead investigational product is belapectin, also known as GR-MD-02. The drug is designed to inhibit galectin-3 and has been studied primarily in patients with advanced liver disease, including nonalcoholic steatohepatitis (NASH) with cirrhosis and portal hypertension. Belapectin is an investigational therapy and has not received regulatory approval.

The company is also evaluating the potential use of galectin-3 inhibition in oncology, including as part of combination approaches intended to improve immune responses against cancer. Galectin Therapeutics was formerly known as Pro-Pharmaceuticals and adopted its current name in 2011. The company is headquartered in Norcross, Georgia, and conducts development activities through clinical research programs; specific commercial geographies are not applicable while its primary product remains investigational.

View Galectin Therapeutics Profile
Earnings Tools